PSORALIDIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H16O5
Molecular Weight	336.338
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)=CCC1=C(O)C=C2OC(=O)C3=C(OC4=CC(O)=CC=C34)C2=C1

InChI

InChIKey=YABIJLLNNFURIJ-UHFFFAOYSA-N

InChI=1S/C20H16O5/c1-10(2)3-4-11-7-14-17(9-15(11)22)25-20(23)18-13-6-5-12(21)8-16(13)24-19(14)18/h3,5-9,21-22H,4H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C20H16O5
Molecular Weight	336.338
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19254011 | https://www.ncbi.nlm.nih.gov/pubmed/18006202 | https://www.ncbi.nlm.nih.gov/pubmed/27428458 | https://www.ncbi.nlm.nih.gov/pubmed/15678382 | https://www.ncbi.nlm.nih.gov/pubmed/24507928

Psoralidin (1) was first isolated from seeds of Psoralea corylifolia Linn. It was found to be an active ingredient of many Indian and Chinese traditional herbal medicines. Psoralidin exhibits a variety of biological activities like antineoplastic, antioxidant, antibacterial, antidepressant activities. Psoralidin inhibits protein tyrosine phosphatase 1B activity. Psoralidin may act as a estrogen receptor agonist. In addition psoralidin showed potent and noncompetitive inhibition against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Protein-tyrosine phosphatase 1B 34 Target ID: CHEMBL335 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15678382	Inhibitor 8297		9.4 µM [IC50]
Estrogen receptor alpha 127 Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24507928	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: http://www.ukjpb.com/article_details.php?id=285	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Fingerprint analysis of Psoralea corylifolia L. by HPLC and LC-MS.	2005 Jul 5	15905140
Antidepressant-like effects of psoralidin isolated from the seeds of Psoralea Corylifolia in the forced swimming test in mice.	2008 Feb 15	18006202
Transcriptional regulation of corticotrophin releasing factor gene by furocoumarins isolated from seeds of Psoralea corylifolia.	2008 May 23	18445497
Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer.	2010 Feb	19851870
Psoralea corylifolia Linn.-"Kushtanashini".	2010 Jan	22228944

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

A cytotoxic coumestan derivative, psoralidin was isolated from the seed of Psoralea corylifolia. The IC50 values of 1 against SNU-1 and SNU-16 carcinoma cell lines were 53 and 203 micrograms/ml, respectively, indicating cytotoxic activity against stomach carcinoma cell lines. Psoralidin was found to be a cytotoxic with the IC50 values of 0.3 and 0.4 microg/ml against the HT-29 (colon) and MCF-7 (breast) human cancer cell lines, respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:32:21 UTC 2023` Edited by `admin` on `Sat Dec 16 09:32:21 UTC 2023`
Record UNII	G16ZUQ069L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PSORALIDIN

Common Name

English

6H-BENZOFURO(3,2-C)(1)BENZOPYRAN-6-ONE, 3,9-DIHYDROXY-2-(3-METHYL-2-BUTENYL)-

Systematic Name

English

PSORALIDIN [MI]

Common Name

English

3-BENZOFURANCARBOXYLIC ACID, 2-(2,4-DIHYDROXY-5-(3-METHYL-2-BUTENYL)PHENYL)-6-HYDROXY-, .DELTA.-LACTONE

Systematic Name

English

Code System Code Type Description

FDA UNII

G16ZUQ069L